Printer Friendly

First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry.

Synthetic cannabinoids are cannabinoid 1 ([CB.sub.1]) [4] and/or CB2 receptor ligands originally developed as pharmacological tools for investigating the endocannabinoid system or as potential pharmacotherapies. Hundreds of compounds were synthesized in academia and pharmaceutical companies, and their binding affinities and structure-activity relationships were investigated (1-3). Since the mid-2000s these designer drugs have been abused as recreational drugs (4-5), leading to numerous intoxications as demonstrated by the high number of poison control calls (6) and emergency department visits over the last few years (7), and also demonstrated by surveys among adolescents that showed high prevalence (8-9). Identifying which substances are currently on the market is a substantial challenge for forensic and clinical laboratories, as well as developing analytical methods for new designer drugs, which requires knowledge of the drugs' metabolism. Synthetic cannabinoids are almost exclusively excreted as metabolites in urine (10-16), the most common screening matrix in clinical, workplace, military, and sport doping drug testing. Therefore, knowledge of urinary metabolites is required for developing effective urine testing methods, but no data on the human metabolism of new compounds are available. Because approval for controlled administration studies in humans cannot be obtained owing to a lack of toxicological data, other strategies are necessary to determine major metabolic targets.


As rapidly as synthetic cannabinoids were scheduled, new compounds emerged. The most popular naphthoylindoles (e.g., JWH-018, AM2201), as well as phenacetylindoles, benzoylindoles, and whole structural classes were scheduled in most European countries, the US, Japan, Russia, Australia, and New Zealand. Consequently, clandestine laboratories synthesized similar nonregulated compounds. One of the newest compounds is [l-(5-fluoropentyl)indol-3-yl]-(2,2,3,3-tetramethyl-cyclopropyl)methanone (XLR-11) (Fig. 1), which replaced former popular substances like AM2201 and JWH-018. XLR-11 is not currently covered by most of the regulations owing to its unusual structural element, the 2,2,3,3-tetramethylcyclopropyl (TMCP) ring. In May 2013, the US Drug Enforcement Administration temporarily placed XLR-11 into Schedule I of the Controlled Substance Act (17). XLR-11 was detected in late 2011 in Russia (18) and also was reported in Japan (19), Europe (20) and the US (21). According to several reports (17, 21), XLR-11 prevalence in the US has increased significantly since the summer of 2012 and remained increased in the beginning of 2013.

TMCP cannabinoids were developed by Abbott Laboratories; synthesis and cannabinoid receptor affinities for 70 compounds were published in 2010 (1). Investigators reported that the TMCP group generally has high CB2 affinity not related to preferred subjective drug effects. Although XLR-11, which has a 5-fluoropentyl side chain at the indole nitrogen, is not mentioned in this publication, the assessment of receptor affinities for 2 closely related compounds, one with a nonfluorinated pentyl side chain and the other with a 5,5,5-trifluoropentyl side chain, was reported. The first compound, also known as UR-144, has high [CB.sub.2] but low [CB.sub.1] receptor-binding affinity ([K.sub.i]) ([K.sub.i] [CB.sub.1], 150 nmol/L; Ki [CB.sub.2], 1.8 nmol/L), whereas the second compound showed high [CB.sub.1] receptor affinity (Ki [CB.sub.1]; 15 nmol/L; Ki [CB.sub.2], 0.09 nmol/L) (1).

The purpose of this study was to investigate human XLR-11 metabolism by analyzing samples collected after drug incubation with human hepatocytes with high-resolution mass spectrometry (HRMS) and software-assisted data mining. This approach creates realistic metabolic profiles because enzyme activities in human hepatocytes produce metabolite concentrations in ratios similar to those found in vivo. Compared to other approaches, e.g., incubation with human liver microsomes or controlled drug administration to rats, human hepatocytes provide the most authentic spectrum of metabolites. Microsomes do not produce phase II metabolites. XLR-11 was selected for this research because of its current high prevalence, the lack of any knowledge on its metabolism in humans, and the serious acute kidney injuries described in adolescents that were associated with XLR-11 in several cases (122-23). Although XLR-11 has not been proven as the causative agent, the parent compound was detected in the implicated product or toxicological results strongly suggested XLR-11 (detection of parent compound in serum or UR-144 pentanoic acid in urine).

Materials and Methods


XLR-11 was obtained from Cayman Chemicals, formic acid for LC-MS from Fisher Scientific, and LC-MS-grade acetonitrile from Sigma Aldrich. Water was purified in house with an ELGA Purelab Ultra Analytic purifier (Siemens Water Technologies).


XLR-11 was incubated at a final substrate concentration of 10 [micro]mol/L with pooled cryopreserved human hepatocytes from 3 donors (Celsis InVitro Technologies) under shaking in an incubator at 37[degrees]C. A 1-mL suspension containing 1.3 million hepatocytes/mL with viability of >80% was used. Samples were collected after 0,1, and 3 h of incubation, mixed with an equal volume of acetonitrile, and stored at -80[degrees]C until analysis. A positive control sample with diclofenac was incubated with XLR-11 and was analyzed for expected metabolites, 4'-hydroxydiclofenac and diclofenac acyl glucuronide, to ensure metabolite formation under the given experimental conditions.


Samples were clarified via centrifugation at 15 000g, 4[degrees]C for 5 min and diluted 1:4 with mobile phase before 10 [micro]L injection. The blank mobile phase, a neat 50 [micro]g/L XLR-11 standard in mobile phases A and B (100 [micro]L/100 [micro]L), and the 0-h sample were analyzed as controls.


Samples were chromatographed on a Shimadzu Prominence HPLC system that consisted of 2 LC-20AD XR pumps, a DGU-20A5R degasser, a SIL-20AC XR autosampler, and a CTO-20 AC column oven. MS data were acquired on an AB SCIEX TripleTOF 5600+ instrument controlled with AB SCIEX Analyst TF (version 1.6) software. Metabolite Pilot (version 1.5) was used for data mining and structure elucidation. A Shimadzu LC-10AD pump and a 10-port W-type diverter valve (VICI; Valeo Instruments) delivered a make-up solution into the ion source in the time periods when the liquid chromatography (LC) flow was diverted to waste. This is recommended for keeping the MS instrument calibration stable.


Gradient elution was performed on a Kinetex C18 column (100 mm x 2.1 mm, 2.6 [micro]m) fitted with a Krud-Katcher Ultra HPLC in-Line cartridge (0.5 [micro]m x 0.1 mm ID, Phenomenex) at 40[degrees]C with 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B) at a flow rate of 0.3 mL/ min. Gradient conditions were: 10% B until 0.3 min, increased to 20% B at 0.5 min, to 80% B at 20.0 min, to 95% B at 20.1 min and held for 1.8 min before column reequilibration at 10% B for 3.0 min. Total run time was 25.0 min. The autosampler temperature was 4[degrees]C.


The MS method consisted of a TOF MS survey scan and an information-dependent acquisition (IDA)-triggered TOF tandem MS (MS/MS) scan with positive electrospray ionization. Source parameters were: source temperature 500[degrees]C, ion spray voltage 5500 V, ion source gases 1 and 2,50 [psi] each; curtain gas 30 [psi]. The TOF scan range was m/z 100-950 Da, with an accumulation time of 0.1 s. The declustering potential was optimized and set to 140 V; the collision energy was 10 eV.

Data were acquired by IDA experiments with dynamic background subtraction with the following specifications: exclusion of isotopes within 3 Da, no exclusion of former target ions, and mass tolerance 50 mDa. Each sample was analyzed with and without mass defect filtering. Mass defect filtering was set with a mass tolerance of 40 mDa for metabolites similar to the parent drug or with major modifications, e.g., dealkylation or glucuronidation, which would markedly change the mass defect (Table 1). A maximum of 4 candidate ions were selected for subsequent product ion scans based on signal intensity. Product ion scans were acquired from 60-950 Da with an accumulation time of 0.075 s per scan. The declustering potential was 140 V. The collision energy was optimized and set to 40 eV with a spread of [+ or -] 10 eV. External mass calibration was performed automatically every fifth injection via infusion through the Calibrant Delivery System.


Data processing was performed with MetabolitePilot software (AB SCIEX). A set of biotransformations for processing the data and assigning appropriate metabolites was created on the basis of the structure of XLR-11. Peaks were considered for metabolite search and MS/MS fragment interpretation if they corresponded to a predicted mass, were within the range of calculated mass defect filters, or showed at least 2 characteristic product ions/neutral losses. The minimum peak width was 2.5 s, minimum peak intensity 1500 cps, MS m/z tolerance 40 ppm, and minimum MS peak intensity 400 cps. The maximum number of unexpected metabolites was restricted to 10. The identified peaks were confirmed as metabolites based on mass accuracy as well as plausible retention time and fragmentation. Major metabolites were determined on the basis of MS peak area ranks, which were assigned within the 1-h and 3-h samples, respectively.


XLR-11 was metabolized by phase I and II enzymes in human hepatocytes; more than 25 XLR-11 metabolites were produced by hydroxylation, carboxylation, hemiketal and hemiacetal formation, internal dehydration, and further glucuronidation of some oxidative metabolites. Mass shifts of the proposed structures compared to calculated exact masses were <2.7 ppm for all metabolites. Retention times were between 5.75 and 13.85 min, with XLR-11 eluting at 17.3 min (Fig. 2A), which provided sufficient time for potential later-eluting metabolites like N-oxides in the 20-min gradient. Notably, XLR-11 also underwent oxidative defluorination resulting in UR-144 metabolites. Table 2 lists all metabolites with retention times, exact masses, assigned biotransformation(s), major fragments, and rank based on MS peak area in the 1 -h and 3 -h samples. Metabolites resulted from hydroxylation (M6, M7, M8, M14, M17, M18, M20, M21) with subsequent ring closure (M23, M30), carboxylation (M11, M13, M14, M18, M27), and oxidative defluorination (M10, M12, M15, M16, M19, M23, M24, M28, M29). Many metabolites underwent further glucuronidation (M1-9, M11, M13, M17, M20-22, M25, M26). Accurate mass measurements and retention times suggested less common metabolic reactions, e.g., hemiacetal formation for M7, M9, and M22, hemiketal formation for M24, and internal dehydration for M23 and M30. No sulfate or glutathione conjugation was observed.

Main sites of metabolic modifications were (a) the terminal position of the pentyl side chain, (b) the TMCP ring, and (c) the [alpha]-carbon atom next to the carbonyl function. Based on MS peak areas and ranking in the 1-h and 3-h samples, the main XLR-11 metabolites were 2'-carboxy-XLR-11 (M27), UR-144 pentanoic acid (M28), 5-hydroxy-UR-144 (M29), 2'-carboxyUR-144 pentanoic acid (M15), and the 3 hydroxy XLR-11 glucuronides (M21, M18, M20).


High-resolution MS acquiring full-scan MS and MS/MS data provides a powerful tool for metabolite identification. The formula of the intact molecule is accurately determined, and accurate mass measurements aid in assigning correct fragment structures. Structure elucidation is easier and faster than with conventional MS requiring multiple injections for precursor ion, neutral loss, and product ion scans.

Some limitations to these first predictions of XLR-11 metabolism should be considered. First, human hepatocytes cannot fully substitute for the complex interactions and processes occurring during metabolism and elimination from the human body. Although human hepatocytes offer the most realistic conditions to determine the metabolic profile of a substance compared with other biological systems, these results predict which metabolites will most likely be found in humans. Second, the cyclopropyl ring is under strain and has been shown to be unstable under certain conditions. Shevyrin et al. (18) and Kavanagh et al. (24) proposed ring opening during 2,2,3,3-TMCP cannabinoid stability studies. The cyclopropyl ring can be cleaved when heated, forming isomers carrying a pent-4-en-1 -one chain. The extent to which this isomerization occurs is unclear, but it should be considered since synthetic cannabinoids are primarily consumed by smoking.



Fig. 1 shows the product ion spectrum of XLR-11 [MO, m/z 330.2229, retention time (RT) 17.33 min]. We related 4 characteristic fragments to a substructure. The 2 most intense fragments are m/z 125, which indicates an intact TMCP ring with the vicinal carbonyl group, and m/z 232, which is the fluoropentyl indole moiety with the carbonyl group attached. Removal of the TMCP ring produces a minor fragment with m/z 97, whereas fragment m/z 144 is the dealkylated carbonyl indole moiety. The other product ions could not be assigned definitively. For structure elucidation of metabolites, mass shifts of product ions between the metabolite and the parent compound will indicate where structure modifications did or did not occur.


Major metabolites were determined by ranking MS peak areas at 1 h and 3 h and combining the results. Fig. 2B shows the extracted ion chromatograms for the 7 most abundant metabolites; Fig. 3 depicts their proposed structures and product ion spectra.

2'-Carboxy-XLR-11 (M27, m/z 360.1976, RT 12.47 min) is the most intense metabolite after 1 h and 3 h of incubation and is therefore the most important XLR-11 metabolite. To date, M27 is specific for identifying XLR-11 consumption. It shows characteristic fragments at m/z 144 and 232, suggesting an unchanged indole moiety and fluoropentyl chain. Indicated by m/z 155 and the absence of m/z 97 and m/z 125 fragment ions, the carboxylation occurs at 1 of the 4 methyl groups, which are stereoisomerically identical. A loss of 46 Da is another indicator for a carboxyl group producing an m/z 314 fragment.

UR-144 pentanoic acid (M28, m/z 342.2073, RT 12.98 min) is derived from XLR-11 after oxidative defluorination--a biotransformation that is already known to occur for other fluorinated synthetic cannabinoids like AM2201 (16). This metabolite displays characteristic product ions at m/z 97 and m/z 125, which are both related to an unaltered TMCP ring, and at m/z 144, an unchanged indole moiety. Fragment m/z 244 indicates that oxidative defluorination at the terminal position of the pentyl side chain occurred, followed by further oxidation. Notably, 5-carboxy-UR-144 is already commercially available. However, it is impossible to unambiguously distinguish between UR-144 and XLR-11 consumption by considering this metabolite only.

5-Hydroxy-UR-144 (M29, m/z 328.2279, RT 13.33 min) is the metabolic precursor of UR-144 pentanoic acid. Characteristic product ions were m/z 97, m/z 125, and m/z 144, suggesting that no modifications take place at the TMCP ring and the indole moiety. Fragment m/z 230 indicates defluorination and hydroxylation at the pentyl side chain. This metabolite also is commercially available to detect XLR-11 intake.

It is consistent that another major XLR-11 metabolite is generated by a combination of the biotransformations that led to the first 2 metabolites. The MS/MS spectrum of 2'-carboxy-UR-144 pentanoic acid (M15, m/z 372.1811, RT 8.58 min) shows fragments at m/z 218 and m/z 244, suggesting a carboxyl function at the end of the pentyl chain, with no modification at the indole moiety (m/z 144). We conclude that the second carboxylation will be located at the TMCP ring since there were no fragments at m/z 97 or m/z 125. The dominant fragment at m/z 354 is generated by a loss of water from the parent; subsequent decarboxylation leads to m/z 310.

Three hydroxy-XLR-11 glucuronides were found (M17, m/z 522.2491, RT 8.89 min; M20, m/z 522.2494, RT 8.98 min; and M21, m/z 522.2497, RT 9.13 min), all of them showing fragments at m/z 144 and m/z 232, which are related to an unchanged indole moiety and fluorinated pentyl side chain. Consequently, the oxidation occurs at the remaining part of the molecule, raising the question why 3 peaks were observed when there are only 2 possible sites for the oxidation to take place. Although a hydroxy group at different methyl groups of the TMCP ring does not lead to sterically different molecules, the introduction of a second chiral center by glucuronidation does. Therefore, we assume that the 2 closely eluting substances (M17 and M20) are diastereomers of 2'-hydroxy-XLR-11 glucuronide, whereas the third compound eluting at 9.14 min (M21) is generated by oxidation at the 1' position, followed by glucuronidation. Oxidation at the exposed methyl group is more likely to occur than at the [alpha]-carbon atom of a carbonyl function, which explains the peak intensities.


(m/z 358, m/z 360, m/z 372, m/z 344, AND m/z 356)

Structure assignments that are particularly interesting are discussed in detail. Fig. 2C shows the extracted ion chromatograms; Fig. 4 presents the proposed structures. Four metabolites with a molecular ion at m/z 358--depicted in dotted line in Fig. 2C--were found at both time points (M10, m/z 358.2016, RT 8.00 min; M12, 358.2016, RT 8.38 min; M16, m/z 358.2016, RT 8.72 min; and M24, m/z 358.2012, RT 9.94 min), with a mass shift suggesting hydroxylation and carboxylation. Three metabolites--M10, M12 and M24--show fragments at m/z 144 and m/z 244 in their MS/MS spectra, which indicate oxidative defluorination to carboxylic acid at the pentyl side chain, leaving hydroxylation for the remaining part of the molecule. The MS/MS spectrum of the fourth metabolite, M16, gives a characteristic fragment at m/z 230, which occurs only for this compound and could be related to oxidative defluorination to form a 5-hydroxypentyl chain. The lack of m/z 97 and m/z 125 indicates carboxylation at the TMCP ring, most probably at an exposed methyl group. With similar product ion spectra and close retention times, M10 and M12 appear to be related, whereas M24 showed different fragments (m/z 200) and eluted later. We suggest that M10 is hydroxylated at the [alpha]-carbon atom while M12 is hydroxylated at a methyl group of the TMCP ring. This is in agreement with calculated logP (octanol-water partition coefficient) values (2.90 vs 2.96) (25) and peak intensities. We propose that M24 is a minor metabolite that is generated by hemiketal formation between the carbonyl group and the hydroxyl group.



In total 3 metabolites were observed with a molecular ion at m/z 372 (depicted in a thin black line in Fig. 2C). Whereas M5 (m/z 372.1807, RT 6.51 min) and M15 (m/z 372.1811, RT 8.58 min) were detected at both time points, M19 is a minor metabolite showing only a small signal in the 3-h sample (m/z 372.1812, RT 8.96). As already mentioned, M15 is one of the major metabolites, 2'-carboxy-UR-144 pentanoic acid. Based on its retention time, we conclude that M5 is the acyl glucuronide of this metabolite. Acyl glucuronides are known to be unstable; they can be cleaved during storage and insource fragmented in the mass spectrometer. Therefore, it is likely that the glucuronide underwent deconjugation and only the molecular ion of the aglycone was detected. For M19, the product ions m/z 144 and m/z 244 in the MS/MS spectrum suggest a carboxyl function at the defluorinated pentyl chain and further biotransformation at the TMCP ring, which probably is the formation of a hemiacetal structure of a hydroxyl group at the 2' position and a reactive aldehyde group at the 3' position. Metabolite M7 (m/z 548.2100, RT 6.76min) is likely the M19 glucuronide, because the product ion spectrum of the precursor 548 shows characteristic fragments at m/z 144, 218,244, 354, and 372. The formation of an ether glucuronide, which is more stable than an acyl glucuronide, also prevents the hemiacetal ring structure from reopening.

The 4 metabolites with molecular ion m/z 360 are depicted in a bold black line in Fig. 2C (M11, m/z 360.1980, RT 8.33 min; M13, m/z 360.1970, RT 8.54 min; M22, m/z 360.1975, RT 9.33 min; and M27, m/z 360.1976, RT 12.47 min). As shown previously, amass shift of 30 Da represents either a carboxylation or an oxidation and an additional ketone formation. Presence of m/z 232 in all product ion spectra excludes the possibility of a modification of the fluoropentyl chain. M27, 2'-carboxy-XLR-l 1, is the most intense metabolite of all observed metabolites. Among the remaining 3 compounds, M13 is clearly more abundant than M11 and M22, which are only minor metabolites. Searching the raw data for m/z 536, the mass of the corresponding glucuronide conjugate, revealed that M13 and M22 are insource fragmented glucuronides. Because relevant signals at m/z 536 could be seen, the mass of [[MH].sup.+] in Table 2 was adjusted accordingly. It is highly probable that Ml 1, which elutes earlier at 8.33 min, is a glucuronide as well. As mentioned before for the hydroxy glucuronides, inclusion of a second chiral center by conjugation with glucuronic acid leads to diastereomers of former identical isomers. This suggests that M11 and M13 are 2 diastereomers of 2,-carboxy-XLR-11 glucuronide, M13 being the primary isomer. M22, which shows the same fragments as the other 3 metabolites, is probably generated by hemiacetal formation followed by glucuronidation.

Dioxidation followed by internal dehydration is the proposed biotransformation for 2 metabolites (M23, m/z 356.1858, RT 9.64 min and M30, m/z 344.2019, RT 13.84 min) (both in grey in Fig. 2C). Both metabolites have an additional aliphatic ring and differ only in the pentyl side chain that is either fluorinated or carboxylated.

Understanding synthetic cannabinoid metabolism is necessary for many reasons. Most importantly, identification of metabolites provides the basis for the development of analytical methods, enabling toxicologists and clinicians to correctly link observed adverse effects to the causative designer drug. Combining epidemiological and clinical data from poison control centers, emergency departments, and police reports with synthetic cannabinoid metabolite concentrations will improve our understanding of the drugs' pharmacodynamic effects and pharmacokinetics, and permit us to better interpret analytical results of these new designer drugs. These data also are critically important for future controlled drug administration studies, should they become possible, and for evaluating the contributions of metabolites that may contribute to pharmacodynamic effects. Chimalakonda et al. showed that some synthetic cannabinoid metabolites may have cannabinoid receptor affinities similar to those of the parent drug (10).


In summary we define here for the first time XLR-11 human metabolism by human hepatocyte culture, high-resolution MS, and software-assisted data mining. XLR-11 is one of the most prevalent new synthetic cannabinoids. Identifying intake of this new designer drug requires that the major metabolites expected in urine are defined. These are the first data on XLR-11 metabolites giving clinical and forensic toxicologists a basis for developing analytical methods, identifying XLR-11 exposure, and interpreting urine results. This approach provides a powerful tool for rapid identification of metabolites of unknown synthetic cannabinoids and will be used for metabolite identification of these and other emerging designer drugs.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: None declared.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: Materials transfer agreement between National Institutes of Health and AB Sciex and the Intramural Research Program, National Institute on Drug Abuse, and National Institutes of Health.

Expert Testimony: None declared.

Patents: None declared.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.


(1.) Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, et al. Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem 2009;53:295-315.

(2.) Fluffman JW. Cannabimimetic indoles, pyrroles and indenes. Curr Med Chem 1999;6:705-20.

(3.) Makriyannls A, Deng FI. Cannabimimetic Indole derivatives. Patent WO/2001/028557, 2001.

(4.) Sedefov R, Gallegos A, Kind L, Lopez D, Auwarter V, Hughes B. EMCDDA 2009 thematic paper--understanding the 'Spice' phenomenon. Office for Official Publications of the European Communities, 2009. cfm/att_80086_EN_SpiceThematicpaperfinalversion. pdf (Accessed August 2013).

(5.) Psychonaut Web Mapping Research Group. Spice report. Institute of Psychiatry, King's College London, 2009. reports/Spice.pdf (Accessed August 2013).

(6.) American Association of Poison Control Centers. Synthetic marijuana data: August 31, 2013. Synthetic_Marijuana_Data_for_Website_8.31. 2013.pdf (Accessed September 2013).

(7.) Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN report: drug-related emergency department visits involving synthetic cannablnoids, 2012. DAWN105/SR105-synthetic-marijuana.pdf (Accessed August 2013).

(8.) Center for Substance Abuse Research. Synthetic marijuana third most reported substance used by US high school students. CESAR FAX. 2013. pdf (Accessed August 2013).

(9.) Stogner JM, Miller BL. A spicy kind of high: a profile of synthetic cannabinoid users. J Subs Use 2013;0:1-7.

(10.) Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, et al. Cytochrome P450-medlated oxidative metabolism of abused synthetic cannabinolds found In K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 2012;40:2174-84.

(11.) Grigoryev A, Kavanagh P, Melnik A. The detection of the urinary metabolites of 1-((5-fluoropentyl)-1 hindol-3-yl]-(2-iodophenyl)methanone (AM-694), a high affinity cannabimimetic, by gas chromatographymass spectrometry. Drug Test Anal 2012;5:110-5.

(12.) Grigoryev A, Kavanagh P, Melnik A. The detection of the urinary metabolites of 3-[(adamantan-1-yl)carbonyl]-1 -pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test Anal 2012;4:519-24.

(13.) Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V. Gas and liguid chromatographymass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:2519-26.

(14.) Hutter M, Broecker S, Kneisel S, Auwarter V. Identification of the major urinary metabolites in man of seven synthetic cannabinolds of the aminoalkylindole type present as adulterants in "herbal mixtures" using LC-MS/MS techniques. J Mass Spectrom 2012;47:54-65.

(15.) Kavanagh P, Grigoryev A, Melnik A, Simonov A. The Identification of the urinary metabolites of 3-(4-methoxybenzoyl)-1-pentylindole (RCS-4), a novel cannabimimetic, by gas chromatographymass spectrometry. J Anal Toxicol 2012; 36:303-11.

(16.) Sobolevsky T, Prasolov I, Rodchenkov G. Detection of urinary metabolites of AM-2201 and UR144, two novel synthetic cannabinoids. Drug Test Anal 2012;4:745-53.

(17.) Department of Justice, Drug Enforcement Administration. Schedules of controlled substances: temporary placement of three synthetic cannabinoids Into schedule, Federal Register Vol. 78, 2013. (Accessed August 2013).

(18.) Shevyrin V, Melkozerov V, Nevero A, Eltsov 0, Morzherin Y, Shafran Y. Identification and analytical properties of new synthetic cannabimimetics bearing 2,2,3,3-tetramethylcyclopropanecarbonyl moiety. Forensic Sci Int 2012;226:62-73.

(19.) Uchiyama N, Kawamura M, Kikura-Hanajlri R, Goda Y. URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 2012;227:21-32.

(20.) European Monitoring Centre for Drugs and Drug Abuse. European database on new drugs, https:// (Accessed May 2013).

(21.) NMS Labs. Designer drug trends report: changes in the designer drug market Spring 2012. www. Update_BKLWebinar_May2012.pdf (Accessed August 2013).

(22.) Center for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use. MMWR Morb Mortal Wkly Rep 2013;62:93-8.

(23.) Thornton SL, Wood C, Friesen MW, Gerona RR. Synthetic cannabinoid use associated with acute kidney Injury. Clin Tox 2013;51:189-90.

(24.) Kavanagh P, Grigoryev A, Savchuk S, Mlkhura I, Formanovsky A. UR-144 in products sold via the Internet: identification of related compounds and characterization of pyrolysis products. Drug Test Anal 2013;5:63892.

(25.) Molinspiration Property Calculation Service. (Accessed May 2013).

Ariane Wohlfarth, [1] Shaokun Pang, [2] Mingshe Zhu, [3] Adarsh S. Gandhi, [1] Karl B. Scheidweiler, [1] Hua-fen Liu, [2] and Marilyn A. Huestis [1] *

[1] Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD; [2] AB SCIEX, Foster City, CA; [3] Department of Biotransformation, Bristol-Myers Squibb Re search and Development, Princeton, NJ.

[4] Nonstandard abbreviations: [CB.sub.1], cannabinoid 1; XLR-11, [1-(5-fluoropentyl)indol-3-yl]-(2,2,3,3- tetramethylcyclopropyl)methanone; TMCP, 2,2,3,3-tetramethy I cyclopropyl; [K.sub.i], receptor-binding affinity; HRMS, high-resolution mass spectrometry; LC, liquid chromatography; IDA, information-dependent acquisition; MS/MS, tandem MS; RT, retention time.

* Address correspondence to this author at: Chemistry and Drug Metabolism, IRP, National Institute on Drug Abuse, National Institutes of Health; Biomedical Research Center; 251 Bayview Blvd. Suite 200 Rm. 05A-721, Baltimore, MD 21224. Fax 443-740-2823; e-mail

Received May 17, 2013; accepted August 20, 2013.

Previously published online at DOI: 10.1373/dinchem.2013.209965
Table 1. Mass defect filters for XLR-11 utilized
during data acquisition and data mining.

Biotransformation             Formula           Molecular
                                                weight. Da

Parent                [C.sub.28][H.sub.28]       329.2155
Glucuronidation       [C.sub.27][H.sub.36]       505.2476
Glutathione           [C.sub.13][H.sub.45]       636.2993
  conjugation           [N.sub.4]][O.sub.7]FS
Sulfation             [C.sub.21][H.sub.28]       409.1723
C5-dealkylation       [C.sub.1]6][H.sub.19]NO    241.1467
Defluorination        [C.sub.21][H.sub.29]NO     311.2249
C5-dealkylation and   [C.sub.22][H.sub.27]       417.1788
  glucuronidation       N[O.sub.7]
Defluorination and    [C.sub.21][H.sub.37]       487.2570
  glucuronidation       N[O.sub.7]

Biotransformation     Width,     Mass
                        Da     defect,

Parent                 100     215.4930

Glucuronidation        100     247.5812

Glutathione            100     299.3004
Sulfation              100     172.3087

C5-dealkylation        100     146.6644
Defluorination         100     224.9148
C5-dealkylation and    100     178.7526
Defluorination and     100     257.0030

Table 2. List with all metabolites sorted by retention
time with molecular weight, major fragments, a rank of
the corresponding peak area in the 1-h and the
3-h -sample, and a description of the biotransformation.

Metabolite   RT,     Name                         Description
ID           min

MO           17.33   Parent

M1           5.21    Not assigned (oxidative      -F +20 -3H
                     defluorination to
                     carboxylic acid confirmed)

M2           5.75    Oxidative defluorination     -F +20 -H
                     to carboxylic acid +         +[C.sub.6][H.sub.8]
                     glucuronidation              [0.sub.6]

M3           6.33    Oxidative defluorination     -F +20 +H
                     + oxidation +                +[C.sub.6][H.sub.8]
                     glucuronidation              [0.sub.6]

M4           6.49    Oxidative defluorination     -F +20 +H
                     + oxidation +                +[C.sub.6][H.sub.8]
                     glucuronidation              [0.sub.6]

M5           6.51    Oxidative defluorination     -F -3H +40
                     to carboxylic acid +         +[C.sub.6][H.sub.8]
                     carboxylation +              [0.sub.6]

M6           6.62    Di-oxidation +               +20 +QHA

M7           6.76    Oxidative defluorination     -F -3H +40
                     to carboxylic acid +         +[C.sub.6][H.sub.8]
                     oxidation + aldehyde         [0.sub.6]
                     formation followed by
                     hemiacetal formation
                     and glucuronidation

M8           7.44    Tri-oxidation +              +30
                     glucuronidation              +[C.sub.6][H.sub.8]

M9           7.86    Oxidative defluorination     -F +20 +H
                     + oxidation +                +[C.sub.6][H.sub.8]
                     glucuronidation              [0.sub.6]

M10          8.00    Oxidative defluorination     -F -H +30
                     to carboxylic acid +

M11          8.33    Carboxylation +              +20 -2H
                     glucuronidation              +[C.sub.6][H.sub.8]
                     (diastereomer 1)             [0.sub.6]

M12          8.38    Oxidative defluorination     -F -H +30
                     to carboxylic acid +

M13          8.54    Carboxylation +              +20 -2H
                     glucuronidation              +[C.sub.6][H.sub.8]
                     (diastereomer 2)             [0.sub.6]

M14          8.56    Carboxylation + oxidation    +30 -2H

M15          8.58    Oxidative defluorination     -F -3H +40
                     to carboxylic acid +

M16          8.72    Oxidative defluorination     -F -H +30
                     + carboxylation

M17          8.89    Oxidation +                  +0
                     glucuronidation              +[C.sub.6][H.sub.8]

M18          8.89    Carboxylation +

M19          8.96    Oxidative defluorination     -F -3H +40
                     to carboxylic acid +
                     oxidation + aldehyde
                     formation followed by
                     hemiacetal formation

M20          8.98    Oxidation +                  +0
                     glucuronidation              +[C.sub.6][H.sub.8]

M21          9.13    Oxidation +                  + 0
                     glucuronidation              +[C.sub.6][H.sub.8]

M22          9.33    Oxidation + aldehyde         +20 -2H
                     formation followed by        +[C.sub.6][H.sub.8]
                     hemiacetal formation         [0.sub.6]
                     + glucuronidation

M23          9.64    Oxidative defluorination     -F +30 -3H
                     to carboxylic acid +
                     Di-oxidation followed
                     by Internal dehydration

M24          9.94    Oxidative defluorination     -F -H +30
                     to carboxylic acid +
                     oxidation + hemiketal

M25          9.97    Oxidative defluorination     -F -H +20
                     to carboxylic acid +         +[C.sub.6][H.sub.8]
                     glucuronidation              [0.sub.6]

M26          10.06   Oxidative defluorination     -F +H +0
                     + glucuronidation            +[C.sub.6][H.sub.8]

M27          12.47   Carboxylation                +20 -2H

M28          12.98   Oxidative defluorination     -F -H +20
                     to carboxylic acid

M29          13.33   Oxidative defluorination     -F +0 +H

M30          13.85   Di-oxidation followed        +0 -2H
                     by internal dehydration

Metabolite   m/z [M-H]+     Major fragments

MO           330.2235       97, 125, 144, 232, 297

M1           340.1910       144, 244

M2           342.2062 (a)   144, 244

M3           520.2535       144, 230, 326, 344

M4           520.2534       144, 230, 326, 344

M5           372.1807 (a)   144, 244, 344

M6           538.2434       144, 248, 344, 362

M7           548.2100       144, 218, 244, 354, 372

M8           554.2389       232, 360, 378

M9           520.2534       125, 246, 344

M10          358.2016       144, 244

M11          360.1980 (a)   206, 232, 298, 342

M12          358.2016       144, 244

M13          536.2294       206, 232, 342

M14          376.1919       144, 204, 248, 314, 358

M15          372.1811       144, 244, 310, 354

M16          358.2016       144, 204, 230, 340

M17          522.2491       144, 232, 328, 346

M18          376.1923       248, 268, 358

M19          372.1812       144, 244, 354

M20          522.2494       144, 232, 328, 346

M21          522.2497       144, 232, 328, 346

M22          536.2294       144, 155, 232, 298, 342

M23          356.1858       144, 244

M24          358.2012       144, 200, 244, 274

M25          518.238        125, 244, 342

M26          504.2595       125, 230, 328

M27          360.1976       206, 232, 342

M28          342.2073       125, 144, 244, 324

M29          328.2279       97, 125, 144, 230

M30          344.2019       144, 232

(a) Potential in-source-fragmentation of the glucuronidated
metabolite because only the mass of the aglycone was found.
COPYRIGHT 2013 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Drug Monitoring and Toxicology
Author:Wohlfarth, Ariane; Pang, Shaokun; Zhu, Mingshe; Gandhi, Adarsh S.; Scheidweiler, Karl B.; Liu, Hua-f
Publication:Clinical Chemistry
Article Type:Report
Date:Nov 1, 2013
Previous Article:Standardization of LC-MS for therapeutic drug monitoring of tacrolimus.
Next Article:Work flow analysis of around-the-clock processing of blood culture samples and integrated MALDI-TOF mass spectrometry analysis for the diagnosis of...

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters